{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:55:33Z","timestamp":1760622933596},"reference-count":23,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T00:00:00Z","timestamp":1388707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Respirology"],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and objective<\/jats:title><jats:p>This study, in a predominantly <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>hinese population, investigated the efficacy and safety of a once\u2010daily (o.d.) inhaled ultra\u2010long\u2010acting \u03b2<jats:sub>2<\/jats:sub>\u2010agonist indacaterol for the treatment of moderate\u2010to\u2010severe chronic obstructive pulmonary disease (<jats:styled-content style=\"fixed-case\">COPD<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a 26\u2010week, double\u2010blind study on randomized patients who received indacaterol 150\u2009\u03bcg or 300\u2009\u03bcg or placebo o.d. The primary variable was trough forced expiratory volume in 1\u2009s (<jats:styled-content style=\"fixed-case\">FEV<jats:sub>1<\/jats:sub><\/jats:styled-content>, average of 23\u2009h 10\u2009min and 23\u2009h 45\u2009min post\u2010dose values) at Week 12. Health status (<jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>t <jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>eorge's <jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>espiratory <jats:styled-content style=\"fixed-case\">Q<\/jats:styled-content>uestionnaire, <jats:styled-content style=\"fixed-case\">SGRQ<\/jats:styled-content>), dyspnoea (transition dyspnoea index, <jats:styled-content style=\"fixed-case\">TDI<\/jats:styled-content>) and safety were evaluated over 26 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 563 patients randomized, 561 (89.8% <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>hinese) received treatment and 482 completed. At Week 12, trough <jats:styled-content style=\"fixed-case\">FEV<jats:sub>1<\/jats:sub><\/jats:styled-content> improved significantly for indacaterol 150 and 300\u2009\u03bcg versus placebo (1.32, 1.29 vs 1.17; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001 for both comparisons), with differences exceeding the pre\u2010specified minimal clinically important difference of 0.12\u2009<jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>. At Week 26, <jats:styled-content style=\"fixed-case\">TDI<\/jats:styled-content> score was superior to placebo for indacaterol 150 and 300\u2009\u03bcg (0.82, 1.15; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01), as was the percentage of patients with a clinically relevant improvement (\u22651 point) (74.1%, 78.6% vs 55.5%; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Both doses provided \u22654\u2010point improvements from baseline in <jats:styled-content style=\"fixed-case\">SGRQ<\/jats:styled-content> score at Week 26 that were numerically greater than placebo (unadjusted means: \u22129.6, \u22128.8 vs \u22127.0), with a similar pattern in percentage of patients with clinically relevant improvements in <jats:styled-content style=\"fixed-case\">SGRQ<\/jats:styled-content> score (65.0%, 61.5% vs 60.6%). Incidences of adverse events were comparable across treatment groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Indacaterol delivered effective bronchodilation with significant improvements in breathlessness and health status in this predominantly Chinese population.<\/jats:p><\/jats:sec>","DOI":"10.1111\/resp.12211","type":"journal-article","created":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T09:14:07Z","timestamp":1388740447000},"page":"231-238","source":"Crossref","is-referenced-by-count":12,"title":["Effect of once\u2010daily indacaterol in a predominantly <scp>C<\/scp>hinese population with chronic obstructive pulmonary disease: A 26\u2010week <scp>A<\/scp>sia\u2010<scp>P<\/scp>acific study"],"prefix":"10.1111","volume":"19","author":[{"given":"Wanzhen","family":"Yao","sequence":"first","affiliation":[{"name":"Peking University Third Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changzheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Xingiao Hospital Third Military Medical University  Chongqing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanshan","family":"Zhong","sequence":"additional","affiliation":[{"name":"Guangzhou Institute of Respiratory Disease  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowen","family":"Han","sequence":"additional","affiliation":[{"name":"People's Hospital of Hebei Province  Shi Jia Zhuang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changgui","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Xijing Hospital  Xi'an China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xixin","family":"Yan","sequence":"additional","affiliation":[{"name":"The Second Hospital of Hebei Medical University  Shi Jia Zhuang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[{"name":"The Second Xiangya Hospital of Central South University  Changsha Hunan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Henley","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Kramer","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,1,3]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD).Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease. Updated2013. [Accessed 4 Mar 2013.] Available from URL:http:\/\/www.goldcopd.org"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61345-8"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200612-1749OC"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.14.7.775"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.125435"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200910-1500OC"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102466\u201010\u201011"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00045810"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2011.02107.x"},{"key":"e_1_2_7_11_1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD).Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease. Updated2007. [Accessed 10 Nov 2011.] Available from URL:http:\/\/www.goldcopd.org"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-200050666"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-200050513"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00099306"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2332\/allergolint.10-OA-0173"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021322"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2008.10.026"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200701-016FM"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.3109\/15412555.2011.594464"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.03.014"},{"key":"e_1_2_7_21_1","first-page":"311","article-title":"Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol\u2010fluticasone","volume":"5","author":"Balint B","year":"2010","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063070"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805800"},{"key":"e_1_2_7_24_1","first-page":"577","article-title":"Theophylline in the treatment of chronic obstructive pulmonary disease: a randomized, double\u2010blind, placebo\u2010controlled study","volume":"29","author":"Zhou YM","year":"2006","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"}],"container-title":["Respirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fresp.12211","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fresp.12211","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/resp.12211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T09:29:32Z","timestamp":1696152572000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/resp.12211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,3]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1111\/resp.12211"],"URL":"https:\/\/doi.org\/10.1111\/resp.12211","archive":["Portico"],"relation":{},"ISSN":["1323-7799","1440-1843"],"issn-type":[{"value":"1323-7799","type":"print"},{"value":"1440-1843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,3]]}}}